Daré Bioscience Receives Final $1M NIH Tranche for DARE-HPV, Advancing HPV Treatment
DARE sits 89% above its 52-week low of $1.27.
Summary
Daré Bioscience received the second and final $1.0 million tranche of a previously announced $2.0 million NIH grant for DARE-HPV, its investigational treatment for high-risk HPV infection. This non-dilutive funding supports non-clinical and translational work for the program. This follows the company's recent initiation of a Phase 2 clinical study for DARE-HPV in May 2026. The funding helps advance a key pipeline asset addressing a significant unmet medical need. Topline data from the Phase 2 study for DARE-HPV is expected in 2027.
At the time of this announcement, DARE was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.5M. The 52-week trading range was $1.27 to $9.19. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.